RINALDI, Luca
 Distribuzione geografica
Continente #
EU - Europa 2.726
NA - Nord America 2.383
AS - Asia 295
SA - Sud America 14
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.432
Nazione #
US - Stati Uniti d'America 2.368
IE - Irlanda 1.190
IT - Italia 554
GB - Regno Unito 339
CN - Cina 186
DE - Germania 172
UA - Ucraina 160
GR - Grecia 82
FR - Francia 65
FI - Finlandia 42
TR - Turchia 40
SE - Svezia 38
RO - Romania 24
IN - India 17
BE - Belgio 16
IR - Iran 14
CA - Canada 11
NL - Olanda 9
ID - Indonesia 8
PK - Pakistan 8
CZ - Repubblica Ceca 7
EG - Egitto 6
RU - Federazione Russa 6
TW - Taiwan 6
CO - Colombia 5
ES - Italia 5
CH - Svizzera 4
JP - Giappone 4
PE - Perù 4
EU - Europa 3
HU - Ungheria 3
MK - Macedonia 3
BR - Brasile 2
CL - Cile 2
HK - Hong Kong 2
MO - Macao, regione amministrativa speciale della Cina 2
MX - Messico 2
MY - Malesia 2
PT - Portogallo 2
RS - Serbia 2
SG - Singapore 2
UG - Uganda 2
VN - Vietnam 2
AN - Antille olandesi 1
AR - Argentina 1
BW - Botswana 1
HR - Croazia 1
KR - Corea 1
LI - Liechtenstein 1
LT - Lituania 1
MA - Marocco 1
PA - Panama 1
SA - Arabia Saudita 1
TN - Tunisia 1
Totale 5.432
Città #
Dublin 1.176
Chandler 425
Jacksonville 291
Princeton 162
Roxbury 157
New York 154
Bremen 105
Cambridge 91
Caserta 85
Medford 74
Naples 64
Ann Arbor 58
Des Moines 51
Wilmington 50
Beijing 46
Napoli 29
Ashburn 27
Redwood City 26
Boardman 25
Nanjing 25
Woodbridge 25
Washington 20
Mountain View 18
Brussels 16
Atlanta 15
Jinan 15
Milan 15
Shenyang 14
Houston 13
San Francisco 12
Giugliano In Campania 11
Helsinki 11
Norwalk 11
Monserrato 10
San Mateo 10
London 9
Timisoara 9
Marano Di Napoli 8
Taizhou 8
Florence 7
Haikou 7
Liveri 7
Munich 7
Stuttgart 7
Zanjan 7
Changsha 6
Hebei 6
Lanzhou 6
Lappeenranta 6
Paris 6
Perugia 6
Sacramento 6
Taipei 6
Tianjin 6
Zhengzhou 6
Amsterdam 5
Aversa 5
Duncan 5
Fairfield 5
Nanchang 5
Philadelphia 5
Samsun 5
Auburn Hills 4
Carinaro 4
Chennai 4
Hangzhou 4
Istanbul 4
Kunming 4
Ningbo 4
Nonantola 4
Pomezia 4
Rho 4
Seattle 4
Zurich 4
Andover 3
Bogotá 3
Bologna 3
Boydton 3
Changchun 3
Dearborn 3
Elora 3
Groningen 3
Hanover 3
Hefei 3
Lima 3
Modugno 3
Mohali 3
Portici 3
Rome 3
Altamura 2
Antea 2
Avellino 2
Bahawalpur 2
Barcelona 2
Belgrade 2
Bonea 2
Brdo 2
Budapest 2
Buffalo 2
Cairo 2
Totale 3.623
Nome #
Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease 100
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 89
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 89
Bartter syndrome 81
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 75
Renal phenotype in bardet-biedl syndrome: A combined defect of urinary concentration and dilution is associated with defective urinary aqp2 and umod excretion 74
Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC) 74
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 69
Chronic HCV infection and neurological and psychiatric disorders: an overview. 63
Genetic characterization of Italian patients with Bardet-Biedl syndrome and correlation to ocular, renal and audio-vestibular phenotype: Identification of eleven novel pathogenic sequence variants 63
ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens. 61
Sonoporation by microbubbles as gene therapy approach against liver cancer 61
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. 59
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 57
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 55
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 54
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 53
Pulsed laser ablation of magnetic nanoparticles as a novel antibacterial strategy against gram positive bacteria 51
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 50
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 50
Spirometry in elderly laryngectomized patients: A feasibility study 50
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 49
HCV-related steatosis and risk of atherosclerosis 49
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 49
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 49
Chronic HCV infection is a risk factor of ischemic stroke 48
Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a real-life setting: A multicentre prospective study 47
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. 46
No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis 46
Aspirin in a Diabetic Retinopathy Setting: insights from NO BLIND Study 46
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy 45
Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment. Predictive Factors and Role of Epigenetics 45
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. 44
COVID-19 and arrhythmia: The factors associated and the role of myocardial electrical impulse propagation. An observational study based on cardiac telemetric monitoring 43
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosi 43
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 43
Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals 43
Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study 43
Hepatic steatosis and necro-inflammatory activity overestimated liver stiffness by transient elastography in staging liver fibrosis in chronic hepatitis C 42
Seasonal variations of hyponatremia in the emergency department: Age-related changes 42
HCC and molecular targeting therapies: Back to the future 42
Chronic Hepatitis C Virus Infection and Depression. 41
Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy 41
Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study 41
The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients 40
Renal handling of uric acid 40
The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy 40
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial 39
A genic and epigenetic combination therapy for liver cancer 39
Atherosclerosis and chronic hepatitis C virus (HCV) infection: Role of liver steatosis 39
A Controversial Case of a Double Hepatic Incidentaloma in a Male Patient with Kidney Failure 39
Cardiac Hypertrophy: from Pathophysiological Mechanisms to Heart Failure Development 39
Role of tight glycemic control during acute coronary syndrome on CV outcome in type 2 diabetes 38
Polypharmacy in older people: Lessons from 10 years of experience with the REPOSI register 38
Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study 38
Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals 38
Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes 38
Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment? 37
ULTRASOUND TIPS IN THE LUNG CANCER DIAGNOSIS: A PILOT STUDY 37
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects? 37
Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early Recognition of Inflamed Thoracic Areas Spreading) 37
Patho-physiology of renal dysfunction in Bardet-Biedl Syndrome 36
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact 36
Cardiovascular benefits from gliflozins: Effects on endothelial function 36
[Next Generation Sequencing and ADPKD] 35
Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) 35
Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study 35
Steatosis is a determinant of fibrosis progression in chronic hepatitis C and is correlated both with body composition and viral factors 34
Cryptogenic cirrhosis is associated with cardiometabolic and oncologic comorbidities and poor liver-related prognosis 34
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 34
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 33
High HDL Cholesterol: a risk factor for Diabetic Retinopathy? Findings from NO BLIND study 33
Editorial – Role of Highly Active Antiretroviral Therapy (HAART) for the COVID-19 treatment 33
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 33
Predictors of in-hospital mortality of COVID-19 patients and the role of telemetry in an internal medicine ward during the third phase of the pandemic 33
Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients 32
Diagnostic performance of LI-RADS in adult patients with rare hepatic tumors 32
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19 32
Nonalcoholic fatty liver disease: Evolving paradigms 31
Non-alcoholic fatty liver disease beyond the liver is an emerging multifaceted systemic disease 31
Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress 31
Hepatocellular carcinoma in patients with cryptogenic and metabolic cirrhosis: Incidence, characteristics, risk factors and survival 31
Atypical presentation of a rare parasitic infection with fasciola hepatica: A multidisciplinary case report 31
Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review 31
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes 31
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors 30
Comment on: Warfarin adherence and anticoagulation control in atrial fibrillation patients-a systematic review 30
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage 29
The importance of the thick ascending limb of Henle's loop in renal physiology and pathophysiology 29
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis. 29
TISSUE RESONANCE INTERACTION METHOD: A CHALLENGE FOR THE EARLY AND NON-INVASIVE DIAGNOSIS OF SOLID CANCERS 29
Editorial - Direct-acting antivirals therapy in HCV patients with HCC: lights and shadow 29
Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. 28
Impact of hepatitis C virus clearance b direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study 28
HCC in HCV patients and the direct acting antivirals: is there really a link? 28
Angiogenesis inhibitors for the treatment of hepatocellular carcinoma 28
Antioxidant diet and genotyping as tools for the prevention of liver disease 28
SARS-CoV-2 vaccine development: Where are we? 28
Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience 27
Management of HBV infection in oncohematologic immunosuppressed patients: lamivudine prohylaxis and rescue therapy of occult HBV infection 27
Totale 4.278
Categoria #
all - tutte 26.617
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.617


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201928 0 0 0 0 0 0 0 0 0 12 13 3
2019/2020554 123 69 10 18 69 18 97 29 24 26 49 22
2020/2021646 29 28 40 32 111 35 149 43 16 39 94 30
2021/20221.037 27 4 20 30 314 20 16 23 72 75 97 339
2022/20232.095 191 64 58 92 262 126 6 108 1.074 21 40 53
2023/2024907 87 33 57 73 330 183 51 38 24 31 0 0
Totale 5.850